What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest ...

What Happened? Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval ...

Medication company Viatris (NASDAQ:VTRS) reported in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The ...

US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic ...

Q2 2025 Earnings Call Transcript August 7, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.62, expectations ...

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors ...

(RTTNews) - Viatris Inc. (VTRS) announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% ophthalmic ointment in ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers.